GCM
VOR icon

Gladius Capital Management’s Vor Biopharma VOR Stock Holding History

Gladius Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$21.2K – 420
2023
Q3 		$21.2K Buy
+500
New +$27.1K ﹤0.01% 338

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Gladius Capital Management's VOR Position: Q4 2023 in Review

Gladius Capital Management sold out of Vor Biopharma (VOR) in Q4 2023, closing a stake of 500 shares — an estimated $21.2K sold.

Gladius Capital Management first reported a position in VOR in Q3 2023 and held it in 1 quarter. The position peaked at $21.2K in Q3 2023. 60 funds tracked by Wall St. Rank hold VOR as of Q4 2023.

  • Gladius Capital Management reported no remaining Vor Biopharma position as of Q4 2023 after selling out during the quarter.
  • Gladius Capital Management sold 500 Vor Biopharma shares in Q4 2023, an estimated $21.2K.
  • Gladius Capital Management first reported a position in Vor Biopharma in Q3 2023 and held it in 1 quarter.
  • Gladius Capital Management's Vor Biopharma position peaked at $21.2K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2023.

Based on Gladius Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.